Beta Drugs Limited announced the completion of its acquisition of 66.09% equity shares in Nivian Lifesciences Private Limited. The transaction involved the transfer of 10,94,535 equity shares, with 64.26% transferred on or before 30th April, 2026, and the remaining shares transferred on 22nd May, 2026. Consequently, Nivian Lifesciences Private Limited became a subsidiary of the company in April.

Acquisition Details

The acquisition was executed under a share swap arrangement. Following the completion, the company will initiate the process for listing approval with the National Stock Exchange of India (NSE) and execute the electronic credit of shares through corporate action. The intimation was submitted pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Context

The company had previously reported total consolidated revenues of Rs 396.0 crores for FY26, a 7.4% increase from Rs 368.8 crores in FY25. The acquisition of Nivian Lifesciences is part of the company's strategic roadmap, "Beta Vision 2030", targeting a revenue mix shift towards branded formulations and exports. Nivian reported revenues of INR 45-46 crores for FY26 with EBITDA margins of 18%-19%.

Beta Drugs Limited has achieved significant regulatory milestones in Azerbaijan and the Philippines, marking important progress in the company's international expansion strategy. These developments strengthen the company's access to CIS and Southeast Asian markets while enhancing export sales opportunities.

Azerbaijan GMP Inspection Success

The company's manufacturing facility underwent a successful inspection by the Ministry of Health of Azerbaijan Republic from April 13, 2026 to April 17, 2026. Beta Drugs expects to receive Good Manufacturing Practice (GMP) approval within the next one to two months following this inspection.

This approval, combined with the company's existing Eurasian Economic Union (EAEU) approval, is expected to enable market entry in Azerbaijan and strengthen commercialization opportunities across the broader CIS region.

Philippines Product Registration Achievement

Beta Drugs has received Certificates of Product Registration (CPR) for two brands in the Philippines market. Both products represent the first generic approvals in their respective categories, providing the company with an opportunity to establish early market presence.

The company anticipates receiving further approvals over the next six months, which are expected to expand its presence in the Philippines and provide a foundation for planned entry into other Southeast Asian markets, including Vietnam and Thailand.

Strengthening International Regulatory Portfolio

These regulatory developments build upon Beta Drugs' existing approvals from PIC/S, ANVISA, INVIMA, and the Eurasian Economic Union (EAEU). The company has also initiated the process for European Union Good Manufacturing Practice (EU GMP) inspection.

These achievements reinforce the company's presence in regulated international markets and are expected to strengthen international filings while supporting future export revenues. The systematic approach to regulatory compliance demonstrates Beta Drugs' commitment to meeting international pharmaceutical standards across multiple jurisdictions.